Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 16/20 | 0.70 |
| ▸ | CNR1 | P21554 | 14/20 | 0.67 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PTGES | O14684 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14367418 | 1.00 | CNR2 (0.70) | CNR2CNR1TAS1R3TAS1R1HTT | |
| SCHEMBL5624238 | 1.00 | CNR2 (0.70) | CNR2CNR1TAS1R3TAS1R1HTT | |
| SCHEMBL5623689 | 0.88 | CNR2 (0.73) | CNR2CNR1TAS1R3TAS1R1 | |
| SCHEMBL5623422 | 0.88 | CNR2 (0.73) | CNR2CNR1TAS1R3TAS1R1 | |
| SCHEMBL14367417 | 0.88 | CNR2 (0.73) | CNR2CNR1TAS1R3TAS1R1 | |
| SCHEMBL14367414 | 0.84 | CNR2 (0.75) | CNR2CNR1TAS1R3TAS1R1 | |
| SCHEMBL5623664 | 0.82 | CNR2 (1.00) | CNR2CNR1TAS1R3TAS1R1 | |
| SCHEMBL14367316 | 0.82 | CNR2 (1.00) | CNR2CNR1TAS1R3TAS1R1 | |
| SCHEMBL5623511 | 0.80 | CNR2 (1.00) | CNR2CNR1MAPT | |
| SCHEMBL5623432 | 0.80 | CNR2 (1.00) | CNR2CNR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7297796-B2 | Sulfamoyl benzamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2007-11-20 | — | — | US | claimed |
| US-20060079557-A1 | Sulfamoyl benzamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2006-04-13 | — | — | US | claimed |
| US-7297796-B2 | Sulfamoyl benzamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2007-11-20 | — | — | US | disclosed |
| WO-2006044645-A2 | SULFAMOYL BENZAMIDES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060079557-A1 | Sulfamoyl benzamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079557-A1 | Sulfamoyl benzamide derivatives and methods of their use | CNR2, TRPV1, CNR1 | CNR2 1/4885CNR1 3/4885TAS1R3 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.